{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:19:48Z","timestamp":1794410388494,"version":"4.9.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Interleukin-6 (IL-6) is an important driver of humoral immunity and a target for treatment of antibody-mediated rejection (AMR) in kidney transplantation. Data on IL-6 inhibition for treatment of AMR are mixed and their efficacy remains inconclusive. In this retrospective observational study, we investigated the association of monthly tocilizumab infusions with the trajectory of estimated glomerular filtration rate (eGFR) among kidney transplant patients with histologic features of chronic active AMR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>Through institutional database review, 85 adult kidney transplant patients with histologic features of chronic active AMR treated with monthly tocilizumab 8\u2009mg\/kg intravenous infusions were identified. Piecewise linear mixed effects models were fitted to compare eGFR trajectories 12 mo before and after tocilizumab initiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>The eGFR declined at a rate of \u20130.70\u2009mL\/min\/1.73 m<jats:sup>2<\/jats:sup>\/mo (95% confidence interval, \u20131.03 to \u20130.36) preceding tocilizumab initiation and stabilized after treatment onset to a slope of \u20130.07 (\u20130.35 to 0.21) mL\/min\/1.73 m<jats:sup>2<\/jats:sup>\/mo (slope difference: 0.59 [0.22-0.97] mL\/min\/1.73 m<jats:sup>2<\/jats:sup>\/mo, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.002).The distribution of the sum mean fluorescence intensity of donor specific antibodies (DSA) among 65 DSA<jats:sup>+<\/jats:sup> patients remained unchanged from baseline to 1 y after treatment; however, 14 of 65 DSA<jats:sup>+<\/jats:sup> patients (22%) no longer had DSA at 1 y. There was 1 graft loss and 2 deaths, both COVID-19-related, by 12 mo after treatment onset.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>This study suggests that monthly treatment with the anti-IL-6 receptor monoclonal antibody, tocilizumab, may stabilize allograft function among kidney transplant patients with chronic active AMR and that further studies to confirm its efficacy should be conducted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001867","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:00:13Z","timestamp":1760641213000},"page":"e1867","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Tocilizumab Treatment for Microvascular Inflammation and Chronic Active Antibody-mediated Rejection in Kidney Transplantation"],"prefix":"10.1097","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5356-9290","authenticated-orcid":false,"given":"Edmund","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8270-2345","authenticated-orcid":false,"given":"Michie","family":"Adjei","sequence":"additional","affiliation":[{"name":"Department of Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3371-0370","authenticated-orcid":false,"given":"Alice","family":"Peng","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6298-0142","authenticated-orcid":false,"given":"Reiad","family":"Najjar","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2505-6372","authenticated-orcid":false,"given":"Jun","family":"Shoji","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-3381","authenticated-orcid":false,"given":"Sindhu","family":"Chandran","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-5331","authenticated-orcid":false,"given":"Ashley","family":"Vo","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-8635","authenticated-orcid":false,"given":"Stanley C.","family":"Jordan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"R1-20251016","doi-asserted-by":"crossref","first-page":"818569","DOI":"10.3389\/fimmu.2022.818569","article-title":"Circulating donor-specific anti-HLA antibodies associate with immune activation independent of kidney transplant histopathological findings.","volume":"13","author":"Van Loon","year":"2022","journal-title":"Front Immunol"},{"issue":"Suppl 4","key":"R2-20251016","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.17207","article-title":"Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts.","volume":"22","author":"Jordan","year":"2022","journal-title":"Am J Transplant"},{"key":"R3-20251016","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients.","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"key":"R4-20251016","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/TP.0000000000004822","article-title":"Chronic active antibody-mediated rejection: opportunity to determine the role of interleukin-6 blockade.","volume":"108","author":"Berger","year":"2024","journal-title":"Transplantation"},{"key":"R5-20251016","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1681\/ASN.2020071106","article-title":"A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection.","volume":"32","author":"Doberer","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R6-20251016","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ekir.2022.01.1074","article-title":"Evaluation of clazakizumab (anti-interleukin-6) in patients with treatment-resistant chronic active antibody-mediated rejection of kidney allografts.","volume":"7","author":"Jordan","year":"2022","journal-title":"Kidney Int Rep"},{"key":"R7-20251016","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ajt.2023.10.016","article-title":"The Banff 2022 Kidney Meeting Report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics.","volume":"24","author":"Naesens","year":"2024","journal-title":"Am J Transplant"},{"key":"R8-20251016","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"R9-20251016","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/TP.0000000000000437","article-title":"Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization.","volume":"98","author":"Kim","year":"2014","journal-title":"Transplantation"},{"key":"R10-20251016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.trim.2013.03.003","article-title":"Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization.","volume":"28","author":"Wu","year":"2013","journal-title":"Transpl Immunol"},{"key":"R11-20251016","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1600-6143.2011.03770.x","article-title":"Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance.","volume":"12","author":"Zhao","year":"2012","journal-title":"Am J Transplant"},{"key":"R12-20251016","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.4049\/jimmunol.1003774","article-title":"Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.","volume":"187","author":"Fogal","year":"2011","journal-title":"J Immunol"},{"key":"R13-20251016","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/s41467-024-48574-w","article-title":"IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice.","volume":"15","author":"Muckenhuber","year":"2024","journal-title":"Nat Commun"},{"key":"R14-20251016","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/ajt.16926","article-title":"Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.","volume":"22","author":"Vo","year":"2022","journal-title":"Am J Transplant"},{"key":"R15-20251016","doi-asserted-by":"crossref","first-page":"e14853","DOI":"10.1111\/ctr.14853","article-title":"Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients.","volume":"37","author":"Khairallah","year":"2023","journal-title":"Clin Transplant"},{"key":"R16-20251016","doi-asserted-by":"crossref","first-page":"e13908","DOI":"10.1111\/ctr.13908","article-title":"Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.","volume":"34","author":"Lavacca","year":"2020","journal-title":"Clin Transplant"},{"key":"R17-20251016","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1097\/TXD.0000000000000988","article-title":"Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients.","volume":"6","author":"Pottebaum","year":"2020","journal-title":"Transplant Direct"},{"key":"R18-20251016","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/ajt.16391","article-title":"Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?","volume":"21","author":"Massat","year":"2021","journal-title":"Am J Transplant"},{"key":"R19-20251016","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/TP.0000000000004784","article-title":"Feasibility of interleukin-6 receptor blockade in cardiac antibody-mediated rejection.","volume":"108","author":"Pottebaum","year":"2024","journal-title":"Transplantation"},{"key":"R20-20251016","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.healun.2023.05.012","article-title":"Tocilizumab for antibody-mediated rejection treatment in lung transplantation.","volume":"42","author":"January","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"R21-20251016","doi-asserted-by":"crossref","first-page":"790547","DOI":"10.3389\/fmed.2021.790547","article-title":"Tocilizumab in the treatment of chronic antibody-mediated rejection post kidney transplantation: clinical and histological monitoring.","volume":"8","author":"Noble","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R22-20251016","doi-asserted-by":"crossref","first-page":"663","DOI":"10.34067\/KID.0000182019","article-title":"Lack of histological and molecular signature response to tocilizumab in kidney transplants with chronic active antibody mediated rejection: a case series.","volume":"1","author":"Kumar","year":"2020","journal-title":"Kidney360"},{"key":"R23-20251016","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.nefroe.2021.06.010","article-title":"Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy.","volume":"42","author":"Chamoun","year":"2022","journal-title":"Nefrologia (Engl Ed)"},{"key":"R24-20251016","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1681\/ASN.2020111558","article-title":"Missing self-induced microvascular rejection of kidney allografts: a population-based study.","volume":"32","author":"Callemeyn","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R25-20251016","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1038\/s41467-019-13113-5","article-title":"Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants.","volume":"10","author":"Koenig","year":"2019","journal-title":"Nat Commun"},{"key":"R26-20251016","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1111\/ajt.15417","article-title":"Back signaling of HLA class I molecules and T\/NK cell receptor ligands in epithelial cells reflects the rejection-specific microenvironment in renal allograft biopsies.","volume":"19","author":"Egelkamp","year":"2019","journal-title":"Am J Transplant"},{"key":"R27-20251016","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1681\/ASN.0000000000000287","article-title":"Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant.","volume":"35","author":"Vincenti","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"R28-20251016","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection.","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"},{"key":"R29-20251016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1681\/ASN.2018070777","article-title":"Archetype analysis identifies distinct profiles in renal transplant recipients with transplant glomerulopathy associated with allograft survival.","volume":"30","author":"Aubert","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R30-20251016","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 Expert Consensus From the Transplantion Society Working Group.","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"R31-20251016","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/TP.0000000000003274","article-title":"Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation.","volume":"105","author":"Irish","year":"2021","journal-title":"Transplantation"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:00:17Z","timestamp":1760641217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001867","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]}}}